Is EINECS 204-522-1 Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use EINECS 204-522-1? Is EINECS 204-522-1 safe for nursing mother and child? Does EINECS 204-522-1 extracts into breast milk? Does EINECS 204-522-1 has any long term or short term side effects on infants? Can EINECS 204-522-1 influence milk supply or can EINECS 204-522-1 decrease milk supply in lactating mothers?
EINECS 204-522-1 lactation summary
- DrLact safety Score for EINECS 204-522-1 is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of EINECS 204-522-1 may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that EINECS 204-522-1 may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using EINECS 204-522-1 .
- Usage of EINECS 204-522-1 is in contradiction to breastfeeding hence if it is must to use EINECS 204-522-1 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About EINECS 204-522-1 usage in lactation
Psychostimulant drug that is used as an anorectic in the treatment of obesity. With similar action than Dexamphetamine. It can cause insomnia, anorexia and nervousness. At latest update no published data were found on excretion into breast milk.Pharmacokinetic data make it likely the passage into milk in an amount that may be significant. Breastfeeding women usually regain their body weight, previous to pregnancy, sooner than those who do not breastfeed. Given the increased risk for cardiac valvular disorders and psychotic reactions, the European Medicines Agency (EMA) ordered the withdrawal from marketing in the European Union on 2000.
Alternate Drugs for Antiobesity preparations. ATC A08
Orlistat(Low Risk)
Sibutramine(Unsafe)
Anfepramone(Dangerous)
Benfluorex-Hcl(Dangerous)
Dexfenfluramine(Unsafe)
Ephedrine(Low Risk)
Fenfluramine(Unsafe)
Phenylpropanolamine(Unsafe)
Phentermine(Dangerous)
Rimonabant(Unsafe)
Ephedrine Hydrochloride(Low Risk)
Ephedrine Sulfate(Low Risk)